The speaker cautioned that one potential outcome of accelerated development includes the possibility of multiple assays being given a positive emergency assessment by regulatory or other review bodies on the basis of manufacturing quality, but Ebola control programmes and implementing agencies still having no clear idea which test or tests to implement. He also noted that assays used in different places would need to do different things (e.g. triage at transit centres, clearance for non-Ebola-related surgical care, support for community care centres with a smaller number of beds).